More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Biologics' share in the industry’s pipeline and in the global pharmaceutical market is increasing, so what are the key issues shaping the current and future direction of biomanufacturing? Industry experts share their perspectives. Gaining an...

Cell and gene therapies are a niche product area, but with manufacturing capacity limited, several companies, including Novartis, Roche, Catalent, and Thermo Fisher, are getting into the market with multi-billion-dollar deals. Inside the cell and...

What have been other important developments from CDMOs, CMOs, and other suppliers thus far in 2019? A look at DCAT member companies making the news. Here are the highlights of announcements from contract development and manufacturing organizations...

What is on the minds of leading pharmaceutical industry executives? The DCAT Week ’19 education programs featured insight on key issues impacting the pharmaceutical industry, manufacturing, and supply. Changes in drug development and the impact on...

At a Congressional hearing last week, executives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., and Pfizer examined drug pricing as part of a larger policy debate on ways to lower prescription drug costs,...

When a global pharmaceutical company’s pediatric formulation and dosage form(s) didn’t fit the plant equipment profile used to manufacture the adult dosage form at the customer’s facility, they needed a high quality, agile CDMO with...

As part of its Drug Competition Action Plan, the US Food and Drug Administration (FDA) has issued draft guidance to outline a new regulatory pathway for “competitive generic therapies” (CGTs) to provide certain incentives for industry to develop...